Targeting agents for enhancing radiation therapy
US8709380B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 5, 2007 |
| Grant date | Apr 29, 2014 |
| Priority date | — |
| Expiry date | May 9, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/6929
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Targeting agents are provided that have an affinity for aberrant cells and tissues. These agents are comprised of chelates, ligands, and/or particles combined with high atomic weight elements so that treatment with ionizing electromagnetic radiation (X-rays, or Gamma rays) results in a higher dose to aberrant cells and tissues than other cells and tissues of a host. The invention further provide methods to enhance the tumor to normal tissue damage ratio by concentrating agents with high atomic number elements to the site of the tumor prior to administering radiotherapy. The result is greater therapeutic efficacy with fewer side effects. These compounds also permit diagnostic uses in combination with the therapeutic use.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.